ArticleFrontiers in immunology2026
Case Report: A case report of bullous pemphigoid triggered by sintilimab (PD-1 inhibitor).
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) can precipitate autoimmune bullous diseases, among which bullous pemphigoid (BP) is uncommon but has significant clinical implications. We report a 72-year-old man with poorly differentiated gastric adenocarcinoma and liver metastases who developed generalized pruritic erythema after the 4th cycle of sintilimab, followed by tense blisters after the 8th cycle. Upon admission (January 2025), over 30% of his body surface area (BSA) was affected, accompanied by pruritus that impacted his sleep. Histopathology showed eosinophilic cell infiltration within the epidermis and mild spongiosis. Edema was observed between collagen fibers in the papillary dermis, accompanied by a small number of lymphocytes and histiocytes. Moderate (+++) mixed inflammatory cell infiltration was observed in the superficial dermis, primarily consisting of lymphocytes (approximately 60%) and eosinophils (approximately 30%), with a small number of neutrophils (approximately 10%). Direct immunofluorescence (DIF) revealed IgG and C3 along the basement membrane zone (BMZ). Serum autoantibodies demonstrated significantly elevated BP180 (392.01 RU/mL) and low BP230 (9.29 RU/mL), while desmoglein-1 (8.38 U/mL) and desmoglein-3 (5 U/mL) were negative/low, supporting BP rather than pemphigus. The rash met the CTCAE (Common Terminology Criteria for Adverse Events) v5.0 criteria for Bullous dermatitis, Grade 3, with concomitant Pruritus, Grade 3. Daily intravenous methylprednisolone 60 mg was initiated, leading to cessation of new blister formation within 7 days and improvement in pruritus. Sintilimab was discontinued during treatment and resumed after BP was brought under control (approximately 1 month later); the patient has maintained remission for more than 12 months since resuming Sintilimab treatment, and no recurrence has been observed. The temporal association with PD-1 blockade, objective clinicopathologic confirmation, and lack of strong alternative culprits support a possible causal relationship. Early biopsy, DIF, and targeted serology enable timely CTCAE-guided management and informed decision-making for pausing or rechallenging PD-1 therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.